Department of Surgery, Boston Medical Center, Boston, MA, USA.
Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.
Ann Surg Oncol. 2024 Mar;31(3):1608-1614. doi: 10.1245/s10434-023-14612-y. Epub 2023 Nov 28.
Initial treatment for nonmetastatic breast cancer is resection or neoadjuvant systemic therapy, depending on tumor biology and patient factors. Delays in treatment have been shown to impact survival and quality of life. Little has been published on the performance of safety-net hospitals in delivering timely care for all patients.
We conducted a retrospective study of patients with invasive ductal or lobular breast cancer, diagnosed and treated between 2009 and 2019 at an academic, safety-net hospital. Time to treatment initiation was calculated for all patients. Consistent with a recently published Committee on Cancer timeliness metric, a treatment delay was defined as time from tissue diagnosis to treatment of greater than 60 days.
A total of 799 eligible women with stage 1-3 breast cancer met study criteria. Median age was 60 years, 55.7% were non-white, 35.5% were non-English-speaking, 18.9% were Hispanic, and 49.4% were Medicaid/uninsured. Median time to treatment was 41 days (IQR 27-56 days), while 81.1% of patients initiated treatment within 60 days. The frequency of treatment delays did not vary by race, ethnicity, insurance, or language. Diagnosis year was inversely associated with the occurrence of a treatment delay (OR: 0.944, 95% CI 0.893-0.997, p value: 0.039).
At our institution, race, ethnicity, insurance, and language were not associated with treatment delay. Additional research is needed to determine how our safety-net hospital delivered timely care to all patients with breast cancer, as reducing delays in care may be one mechanism by which health systems can mitigate disparities in the treatment of breast cancer.
非转移性乳腺癌的初始治疗方法是切除术或新辅助系统治疗,这取决于肿瘤生物学和患者因素。治疗的延迟已被证明会影响生存和生活质量。关于保障医院为所有患者提供及时护理的表现,发表的相关内容很少。
我们对 2009 年至 2019 年在一所学术性保障医院诊断和治疗的浸润性导管或小叶性乳腺癌患者进行了回顾性研究。对所有患者的治疗开始时间进行了计算。根据最近发表的癌症委员会及时性指标,将治疗延迟定义为从组织诊断到治疗的时间超过 60 天。
共有 799 名符合条件的 1-3 期乳腺癌患者符合研究标准。中位年龄为 60 岁,55.7%为非白人,35.5%为非英语患者,18.9%为西班牙裔,49.4%为医疗补助/无保险。中位治疗时间为 41 天(IQR 27-56 天),而 81.1%的患者在 60 天内开始治疗。种族、族裔、保险和语言与治疗延迟的发生频率无关。诊断年份与治疗延迟的发生呈负相关(OR:0.944,95%CI 0.893-0.997,p 值:0.039)。
在我们的机构中,种族、族裔、保险和语言与治疗延迟无关。需要进一步研究,以确定我们的保障医院如何为所有乳腺癌患者提供及时护理,因为减少护理延迟可能是医疗系统减轻乳腺癌治疗差异的一种机制。